Share on StockTwits

Shares of Shire PLC (LON:SHP) have been given a consensus recommendation of “Buy” by the twenty-six brokerages that are covering the stock, American Banking and Market News reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation, seventeen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is GBX 3,683.43 ($61.98).

Shares of Shire PLC (LON:SHP) opened at 4543.00 on Monday. Shire PLC has a one year low of GBX 2356.00 and a one year high of GBX 5050.00. The stock’s 50-day moving average is GBX 4677.95 and its 200-day moving average is GBX 3593.. The company’s market cap is £26.640 billion.

The company also recently announced a dividend, which is scheduled for Friday, October 3rd. Investors of record on Wednesday, September 3rd will be paid a dividend of GBX 2.24 ($0.04) per share. This represents a dividend yield of 0.04%. The ex-dividend date is Wednesday, September 3rd.

SHP has been the subject of a number of recent research reports. Analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of Shire PLC in a research note on Friday, July 25th. They now have a GBX 5,300 ($89.18) price target on the stock. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Shire PLC in a research note on Monday, July 21st. They now have a GBX 5,200 ($87.50) price target on the stock. Finally, analysts at Kepler Capital Markets reiterated a “buy” rating on shares of Shire PLC in a research note on Tuesday, July 15th. They now have a GBX 5,100 ($85.82) price target on the stock.

Shire plc (LON:SHP) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.